Dasatinib (Cat No.:A000288) is a potent tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with the Philadelphia chromosome. It works by inhibiting the BCR-ABL kinase, which is responsible for the uncontrolled growth of leukemic cells. Dasatinib also targets other kinases like Src family kinases, enhancing its efficacy against resistant cancer cells. Known for its rapid action and high response rates, Dasatinib is an essential therapy for managing CML and Ph+ ALL, significantly improving patient survival and quality of life.
| Catalog Number | A000288 |
| CAS Number | 302962-49-8 |
| Synonyms | BMS-354825 |
| Molecular Formula | C22H26ClN7O2S |
| Purity | 95% |
| Target | Bcr-Abl |
| Solubility | >24.4mg/mL in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide |
| InChI | InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) |
| InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO |
